Singapore to expedite evaluation of Sanofi's dengue vaccine | Biogen faces IPR challenge over 3 Tysabri patents | Company resurrects abandoned cholesterol drug
April 21, 2016
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science
Top Story
Singapore to expedite evaluation of Sanofi's dengue vaccine
Sanofi's dengue vaccine Dengvaxia is being fast-tracked by Singapore's Health Sciences Authority, which hopes to make an approval decision in six months instead of the standard nine-month time frame. Sanofi filed the registration application in March.
Channel NewsAsia (4/20) 
LinkedIn Twitter Facebook Google+ Email
Biogen faces IPR challenge over 3 Tysabri patents
Swiss Pharma International has challenged three patents related to the formulation and preparation of Biogen's multiple sclerosis drug Tysabri natalizumab by filing inter partes review petitions with the US Patent and Trademark Office. The petitions claim that, on the grounds of obviousness based on prior art, the patents should not have been granted.
BioCentury (4/19) 
LinkedIn Twitter Facebook Google+ Email
Company resurrects abandoned cholesterol drug
London-based DalCor Pharmaceuticals is recruiting 5,000 patients for a clinical trial of a cholesterol drug that Roche abandoned after it failed to meet endpoints in a Phase III trial. The drug showed promise in a subset of patients with a certain genetic variation, and only patients with that variant will be recruited.
The Wall Street Journal (tiered subscription model) (4/19) 
LinkedIn Twitter Facebook Google+ Email
Asia Pacific
Generic-drug makers expand and seek more approvals
Generic-drug makers in India including Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and Lupin are investing in research and development capacity, and are applying for FDA approval of drug combinations and delivery methods as well as modified versions of existing drugs.
The Wall Street Journal (tiered subscription model) (4/19) 
LinkedIn Twitter Facebook Google+ Email
North America
Implantable microdevice shows promise in selecting best cancer therapy
A second-generation microdevice developed by Massachusetts Institute of Technology researchers can identify the best of 100 therapeutic options for a patient with cancer, according to preclinical data from a trial presented at the American Association for Cancer Research's annual meeting. The device is designed to release drugs at a tumor site where it is implanted, then be retrieved after 24 hours along with surrounding tissue for analysis.
Medscape (free registration) (4/19) 
LinkedIn Twitter Facebook Google+ Email
Immunotherapy continues to show promise
Two recent studies found that recurrent, difficult-to-treat head-and-neck cancer and Merkel cell carcinoma respond to immunotherapies. The studies indicate that "virus-driven cancers can be amenable to treatment by immunotherapy," said Paul Nghiem, who led the carcinoma study.
The Washington Post (tiered subscription model) (4/19) 
LinkedIn Twitter Facebook Google+ Email
Government price controls would disrupt Part D
Allowing the federal government to negotiate Medicare prices with drugmakers would limit choice for seniors, says Pharmaceutical Care Management Association President and CEO Mark Merritt. "Many don't know that price controls require a one-size-fits-all, national drug list that's built and run by the government. That would completely disrupt Medicare Part D and restrict choices for seniors," Merritt said.
USA Today (4/19) 
LinkedIn Twitter Facebook Google+ Email
Roche files patent suit over Indian-made anemia drug
Roche filed suit against India-based Intas Pharmaceuticals, charging infringement of patent rights of Mircera, an injectable used to treat anemia in chronic kidney disease. Roche has requested an injunction order from the Delhi High Court.
The Economic Times (India) (4/18) 
LinkedIn Twitter Facebook Google+ Email
Patents sought for Faron's cancer therapy
Two patent applications were filed by Faron Pharmaceuticals in Finland for Clevegen, a cancer drug that can stimulate the body's immune responses to fight the disease. The patents could be applied worldwide through the Patent Co-operation Treaty. (U.K.) (4/19) 
LinkedIn Twitter Facebook Google+ Email
DIA News
Stay up-to-date on clinical safety, pharmacovigilance and drug safety
LinkedIn Twitter Facebook Google+ Email
Learn more about DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
Press Releases
Post a Press Release
The speed of your success is limited only by your dedication and what you're willing to sacrifice.
Nathan Morris,
financial coach and writer
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information